The hemophilia treatment market is witnessing continuous growth. Increasing number of hemophilic patients worldwide is driving the demand for recombinant and plasma derived factor VIII and factor IX, which are used to treat hemophilia. In addition, increased diagnosis rate and rise in the use of prophylactic treatment for hemophilia are expected to propel the growth of this market. However, the high cost of recombinant products, serious adverse effects associated with plasma derived products, and stringent government regulations are hampering the growth of the global hemophilia market to a certain extent.
In this report, the hemophilia treatment market is segmented by product, type, and region. Based on type of product, the hemophilia treatment market is mainly segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, and antifibrinolytics. Plasma derived coagulation factor concentrates is further subsegmented into factor VIII, factor IX, factor XIII, active promthrombin complex concentrates, and von Willebrand factor. Recombinant coagulation factor concentrates is further sugsegmented into factor VIII, factor IX, and von Willebrand factor. By type, hemophilia treatment market is segmented into hemophilia A, hemophilia B, and hemophilia C.
North America is the largest regional segment of the global hemophilia market. However, the APAC and Latin American regions are expected to witness significant growth in the near future, primarily rising number of hemophilic patients, and increasing awareness about technologically advanced products in these regions. Moreover, owing to better diagnostic technique, increasing prophylactic treatments, and growing medical research in the APAC and LATAM, the demand for recombinant and plasma derived products are further increasing in these regions.
The global hemophilia market is mainly dominated by six players that accounted for around 90% of the global hemophilia market in 2013. However, new local players in the market are intensifying competition and thereby threatening the market share of existing players. In order to maintain their shares, leading players are continuously adopting various strategies. This increased competitiveness is expected to drive innovation in the market and thereby help the industry to solve existing challenges and meet the needs of the market.
The major players in the global hemophilia market are Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Novo Nordisk (Denmark), Kedrion (Italy), Pfizer, Inc. (U.S.), Bayer AG (Germany), Biogen Idec, Inc. (U.S.), and Hospira, Inc. (U.S.) .
Plasma derived coagulation factor concentrates and recombinant coagulation factor concentrates are the primary drug of choice for the treatment of hemophilia. Increasing number of hemophilic patients across the globe is increasing the demand of hemophilia treatment products such plasma derived coagulation factor concentrates, recombinant coagulation factor, desmopressin, and antifibrinolytics.
Global Hemophilia Treatment Market
This research report categorizes the hemophilia treatment market into the following segments:
Hemophilia Treatment Market, by product
Hemophilia Treatment Market, by type
Global Hemophilia Treatment Market, By Region
Benchmarking the rapid strategy shifts of the Top 100 companies in the Hemophilia Treatment MarketRequest For Special Pricing